EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation

Nadia Abdel Wahed, Hala Abdellatif, Yasin K. Ahmed, Dima Abdul Jabbar

Global Advances in Oncology and Hematology · 2026-09 · 1 (1) · 31-35

DOI: 10.4103/gaoh.gaoh_2_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Advances in Oncology and Hematology, online erschienen am 05.09.2026. Verfasst von Nadia Abdel Wahed und 3 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wahed, N. A., Abdellatif, H., Ahmed, Y. K., & Jabbar, D. A. (2026). The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation. Global Advances in Oncology and Hematology, 1(1), 31-35. https://doi.org/10.4103/gaoh.gaoh_2_26

Vancouver

Wahed NA, Abdellatif H, Ahmed YK, Jabbar DA. The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation. Global Advances in Oncology and Hematology. 2026;1(1):31-35. doi:10.4103/gaoh.gaoh_2_26

BibTeX
@article{Wahed2026,
  author = {Wahed, Nadia Abdel and Abdellatif, Hala and Ahmed, Yasin K. and Jabbar, Dima Abdul},
  title = {The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation},
  journal = {Global Advances in Oncology and Hematology},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {31--35},
  doi = {10.4103/gaoh.gaoh_2_26}
}
Kostenlos starten →